zepbound or semaglutide vs GLP-1 vs Wegovy: What's the Difference Zepbound Beats Wegovy in the

Start with one teaspoon a day, potentially increasing to 2-3 teaspoons per day if necessary

Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes

Thakkar N, Gajera G, Mehta D, Nair S, Kothari V (2025) Withania somnifera root extract (LongeFera) confers beneficial effects on health and lifespan of the model worm Caenorhabditis elegans

Back to Journals Drug Design, Development and Therapy Volume 20 GLP-1 Receptor Agonists in Neurological Disorders: From Mechanisms to Clinical Translation Received 1 April 2026 Accepted for publication 2 June 2026 Published 12 June 2026 Volume 2026:20 613616 DOI Checked for plagiarism Yes Review by Single anonymous peer review Peer reviewer comments 4 Editor who approved publication: Professor Anastasios Lymperopoulos Pengpeng Li, Yangyang Gao, Wei Liu Department of Neurosurgery, Xian Aerospace Hospital of Northwest University, Xian, Shanxi, 710000, Peoples Republic of China Correspondence: Pengpeng Li, Email [email protected] Wei Liu, Email [email protected] Abstract: Glucagon-like peptide-1 receptor agonists, or GLP-1RAs, have been used for years to treat type 2 diabetes and obesity